Current Status
Not Enrolled
Price
Free
Get Started

Global ASCVD Trends and Emerging Strategies

Program Director

Peter Libby, MD

Program Director

Raul D Santos, MD, MSc, PhD

The IAS has developed the worldwide effort aimed at health care professionals to comprehensively address the matter of LDL-C attributable risk in the prevention of Major Adverse Cardiology Events (MACE) and mortality  This will be accomplished through a series of nine (9) videos presented by some of the most recognizable and prominent leaders in cardiology and lipid medicine from across the globe. 

Importantly, the videos will emphasize the translation of current guidelines and evidence into practice approaches that heighten both clinical and patient success.  Every video, based on real-world issues and evidence, will focus on implementing practical physician and patient strategies. 

The videos are presented in
English, but we have added subtitles in four (4) additional languages:  Arabic, Spanish, Portuguese and Chinese.  

            Click on the button of your preferred language below.

ASCVD Square with Title

Pre-Activty Information

Not available

Futuras terapias para o tratamento da dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

See more...

Not available

Uso de inibidores de PCSK9 em pacientes com hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

See more...

Not available

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins

See more...

Not available

Video 9 – Future Therapies for Dyslipidemia Treatment – Chinese

See more...

Not available

Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients – Chinese

See more...

Not available

Video 7 – Efficacy, Feasibility and Safety of Early Use of Monoclonal PCSK9 Inhibitors After an Acute Coronary Syndrome – Chinese

See more...

Not available

Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness – Chinese

See more...

Not available

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins – Chinese

See more...

Not available

Video 4 – Safety of Intensive LDL-C Reduction – Chinese

See more...

Not available

Video 3 – For ASCVD Prevention the Lower the LDL-C the Better – Chinese

See more...

Not available

Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide – Chinese

See more...

Not available

Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease – Chinese

See more...

Not available

Futuras terapias para el tratamiento de la dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

See more...

Not available

Uso de inhibidores de PCSK9 en pacientes con hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

See more...

Not available

Eficacia, viabilidad y seguridad del uso temprano de inhibidores monoclonales de PCSK9 después de un síndrome coronario agudo (Video 7 – Efficacy, Feasibility and Safety of Early Use of Monoclonal PCSK9 Inhibitors After an Acute Coronary Syndrome)

See more...

Not available

Impacto de la inhibición de PCSK9 en pacientes de muy alto riesgo y cómo aumentar la rentabilidad (Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness)

See more...

Not available

Impacto del bloqueo de la PCSK9 circulante con anticuerpos monoclonales sobre las lipoproteínas aterogénicas (Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins)

See more...

Not available

Seguridad de la reducción intensiva de LDL-C (Video 4 – Safety of Intensive LDL-C Reduction)

See more...

Not available

Para la prevención de ASCVD, cuanto menor sea el LDL-C, mejor (Video 3 – For ASCVD Prevention the Lower The LDL-C the Better)

See more...

Not available

La triste e inadecuada realidad del control del colesterol en todo el mundo (Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide)

See more...

« » page 1 / 9